Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
China · Delayed Price · Currency is CNY 16.89
-0.01 (-0.06%)
Apr 30, 2026, 2:04 PM CST
SHE:002932 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 265.08 | 350.01 | 749.49 | 10,530 | 2,830 |
Other Revenue | - | 0.05 | 0.05 | - | - |
| 265.08 | 350.06 | 749.54 | 10,530 | 2,830 | |
Revenue Growth (YoY) | -24.28% | -53.30% | -92.88% | 272.12% | 195.05% |
Cost of Revenue | 169.21 | 217.75 | 309.72 | 3,992 | 707.41 |
Gross Profit | 95.87 | 132.31 | 439.82 | 6,538 | 2,122 |
Selling, General & Admin | 140.7 | 165.41 | 218.97 | 591.45 | 273.23 |
Research & Development | 85.78 | 109.55 | 141.42 | 388.36 | 132.74 |
Other Operating Expenses | -24.66 | 0.82 | 1.41 | 59.79 | 12.8 |
Operating Expenses | 201.81 | 278.62 | 446.93 | 1,403 | 439.59 |
Operating Income | -105.95 | -146.31 | -7.11 | 5,135 | 1,683 |
Interest Expense | - | -1.28 | -10.5 | -3.42 | -2.11 |
Interest & Investment Income | 104.83 | 144.1 | 124.94 | 52.85 | 12.36 |
Currency Exchange Gain (Loss) | - | 0.65 | 1.22 | 21.52 | -3.13 |
Other Non Operating Income (Expenses) | -49.14 | -1.37 | -1.23 | -1.35 | -1.08 |
EBT Excluding Unusual Items | -50.26 | -4.22 | 107.31 | 5,205 | 1,689 |
Gain (Loss) on Sale of Investments | -0.86 | 1.74 | 4.59 | 2.76 | - |
Gain (Loss) on Sale of Assets | 0.66 | 1.79 | 0.31 | 0.01 | - |
Asset Writedown | -13.32 | -34.87 | -38.02 | -147.03 | - |
Other Unusual Items | - | 67.97 | 65.7 | 15.91 | 5.69 |
Pretax Income | -63.79 | 32.42 | 139.89 | 5,076 | 1,695 |
Income Tax Expense | 11.27 | 5.85 | 70.67 | 695.84 | 247.87 |
Earnings From Continuing Operations | -75.06 | 26.56 | 69.22 | 4,381 | 1,447 |
Minority Interest in Earnings | 58.6 | 47.95 | 5.71 | -172.06 | -33.46 |
Net Income | -16.46 | 74.52 | 74.93 | 4,208 | 1,413 |
Net Income to Common | -16.46 | 74.52 | 74.93 | 4,208 | 1,413 |
Net Income Growth | - | -0.54% | -98.22% | 197.79% | 201.37% |
Shares Outstanding (Basic) | 235 | 226 | 227 | 228 | 212 |
Shares Outstanding (Diluted) | 235 | 226 | 227 | 230 | 212 |
Shares Change (YoY) | 4.13% | -0.54% | -1.22% | 8.61% | 1.43% |
EPS (Basic) | -0.07 | 0.33 | 0.33 | 18.46 | 6.68 |
EPS (Diluted) | -0.07 | 0.33 | 0.33 | 18.31 | 6.68 |
EPS Growth | - | - | -98.20% | 174.19% | 197.11% |
Free Cash Flow | -160.95 | -269.81 | 282.52 | 3,699 | 1,023 |
Free Cash Flow Per Share | -0.68 | -1.20 | 1.24 | 16.09 | 4.84 |
Dividend Per Share | - | 1.230 | 0.120 | 3.490 | 2.027 |
Dividend Growth | - | 925.00% | -96.56% | 72.18% | 214.98% |
Gross Margin | 36.17% | 37.80% | 58.68% | 62.09% | 75.00% |
Operating Margin | -39.97% | -41.80% | -0.95% | 48.77% | 59.47% |
Profit Margin | -6.21% | 21.29% | 10.00% | 39.97% | 49.94% |
Free Cash Flow Margin | -60.72% | -77.08% | 37.69% | 35.13% | 36.17% |
EBITDA | -54.25 | -89.26 | 59.3 | 5,180 | 1,704 |
EBITDA Margin | -20.47% | -25.50% | 7.91% | 49.19% | 60.22% |
D&A For EBITDA | 51.7 | 57.05 | 66.41 | 45.04 | 21.28 |
EBIT | -105.95 | -146.31 | -7.11 | 5,135 | 1,683 |
EBIT Margin | -39.97% | -41.80% | -0.95% | 48.77% | 59.47% |
Effective Tax Rate | - | 18.05% | 50.52% | 13.71% | 14.63% |
Revenue as Reported | - | 350.06 | 749.54 | 10,530 | 2,830 |
Advertising Expenses | - | 9.87 | 12.13 | 56.66 | 23.94 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.